Rigel Announces Webcast of Investor Day on May 6, 2014

            Rigel Announces Webcast of Investor Day on May 6, 2014

-- Company to Give Overview of Product Portfolio and Strategy --

PR Newswire

SOUTH SAN FRANCISCO, Calif., April 30, 2014

SOUTH SAN FRANCISCO, Calif., April 30, 2014 /PRNewswire/ --Rigel
Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will host an
Investor Day on Tuesday, May 6, 2014 from 9:30 a.m. to 12:00 p.m. E.T. in New
York City. Rigel management will provide an overview of the company's product
portfolio and discuss future strategy.

Donald G. Payan, M.D., executive vice president and president of discovery and
research of Rigel, will provide an overview of Rigel's product portfolio,
including an outline of its upcoming Phase 3 studies of fostamatinib in
patients with Immune Thrombocytopenic Purpura (ITP).

At the event, James B. Bussel, M.D., a leading expert on ITP and professor of
pediatrics in medicine, Weill Cornell Medical College, will comment on
fostamatinib and treatment options for ITP.

To access the live audio webcast or the subsequent archived recording, log on
to www.rigel.com. Please connect to Rigel's website several minutes prior to
the start of the live webcast to ensure adequate time for any software
download that may be necessary.

About Rigel (www.rigel.com)

Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that
discovers and develops novel, small-molecule drugs for the treatment of
inflammatory and autoimmune diseases, as well as muscle disorders. Rigel's
pioneering research focuses on intracellular signaling pathways and related
targets that are critical to disease mechanisms. Rigel currently has five
product candidates in development: fostamatinib, an oral SYK inhibitor
expected to enter Phase 3 clinical trials for ITP in the second quarter of
2014 and a Phase 2 clinical trial for IgA nephropathy in the second half of
2014; R348, a topical JAK/SYK inhibitor currently in Phase 2 clinical trials
for dry eye; R118, an AMPK activator in Phase 1 development; and two oncology
product candidates in Phase 1 development with partners BerGenBio and Daiichi

Contact: Raul Rodriguez
Phone: 650.624.1302
Email: invrel@rigel.com

Media Contact: Susan C. Rogers, Rivily, Inc.
Phone: 650.430.3777
Email: susan@rivily.com

SOURCE Rigel Pharmaceuticals, Inc.

Website: http://www.rigel.com
Press spacebar to pause and continue. Press esc to stop.